NCT05005728Phase 2Completed

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Study sponsor: Xencor, Inc. · XNCR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-10Actual
Enrollment · participants72Actual
Source updated2026-05-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview